TSE:ONC FY2024 EPS Estimate Decreased by Cantor Fitzgerald

Oncolytics Biotech Inc. (TSE:ONC) – Stock analysts at Cantor Fitzgerald dropped their FY2024 EPS estimates for Oncolytics Biotech in a research report issued on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now forecasts that the company will post earnings per share of ($0.42) for the year, down from their previous estimate of ($0.36). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share.

Separately, Raymond James raised Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.

Oncolytics Biotech Price Performance

Shares of TSE ONC opened at C$1.48 on Monday. The company has a quick ratio of 8.86, a current ratio of 4.99 and a debt-to-equity ratio of 6.09. The business’s 50 day moving average price is C$1.50 and its two-hundred day moving average price is C$1.45. The company has a market cap of C$113.75 million, a PE ratio of -3.68 and a beta of 1.35. Oncolytics Biotech has a twelve month low of C$1.15 and a twelve month high of C$2.32.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.